Autopsy report · NCT00802659

A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain

“Terminated due to low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months after it had already started.
• Ran for about 9 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 5 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Metastases

Interventions

Stereotactic radiotherapy

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
  “Terminated due to poor accrual” (95% match in meaning)
• Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
  “Terminated prematurely due to low accrual.” (90% match in meaning)
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
  “Terminated due to slow accrual” (88% match in meaning)
• Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
  “Terminated due to inadequate rate of accrual.” (85% match in meaning)
• Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
  “Low accrual and early termination” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.